[go: up one dir, main page]

AU2001236868A1 - Ophthalmic use of alpha adrenergic blocking agents - Google Patents

Ophthalmic use of alpha adrenergic blocking agents

Info

Publication number
AU2001236868A1
AU2001236868A1 AU2001236868A AU3686801A AU2001236868A1 AU 2001236868 A1 AU2001236868 A1 AU 2001236868A1 AU 2001236868 A AU2001236868 A AU 2001236868A AU 3686801 A AU3686801 A AU 3686801A AU 2001236868 A1 AU2001236868 A1 AU 2001236868A1
Authority
AU
Australia
Prior art keywords
blocking agents
ophthalmic use
alpha adrenergic
adrenergic blocking
ophthalmic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001236868A
Inventor
Miles A. Galin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of AU2001236868A1 publication Critical patent/AU2001236868A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4168—1,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/417—Imidazole-alkylamines, e.g. histamine, phentolamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2001236868A 2000-02-10 2001-02-09 Ophthalmic use of alpha adrenergic blocking agents Abandoned AU2001236868A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/501,400 US6730691B1 (en) 2000-02-10 2000-02-10 Uses of alpha adrenergic blocking agents
US09501400 2000-02-10
PCT/US2001/004316 WO2001058438A1 (en) 2000-02-10 2001-02-09 Ophthalmic use of alpha adrenergic blocking agents

Publications (1)

Publication Number Publication Date
AU2001236868A1 true AU2001236868A1 (en) 2001-08-20

Family

ID=23993399

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001236868A Abandoned AU2001236868A1 (en) 2000-02-10 2001-02-09 Ophthalmic use of alpha adrenergic blocking agents

Country Status (10)

Country Link
US (1) US6730691B1 (en)
EP (1) EP1255540A1 (en)
JP (1) JP2003535817A (en)
KR (1) KR20030061301A (en)
AU (1) AU2001236868A1 (en)
BR (1) BR0108219A (en)
CA (1) CA2398158A1 (en)
IL (1) IL151171A0 (en)
MX (1) MXPA02007698A (en)
WO (1) WO2001058438A1 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6730065B1 (en) * 2000-09-15 2004-05-04 Ocularis Pharma, Inc. Night vision composition
US20020082288A1 (en) * 1999-09-16 2002-06-27 Gerald Horn Ophthalmic formulations comprising an imidazoline
US20060211753A1 (en) * 2000-11-03 2006-09-21 Ocularis Pharma, Inc. Method and composition which reduces stimulation of muscles which dilate the eye
FR2874811B1 (en) * 2004-09-03 2006-11-24 Anteis Sa ANTIPHOTOPHOBIC OCULAR DEVICE AND METHOD FOR PREPARING THE SAME
JP5098156B2 (en) * 2005-11-16 2012-12-12 大正製薬株式会社 Water secretion promoter
US20070154523A1 (en) * 2005-12-30 2007-07-05 Rick Lewis Controlled pupil dilation for diagnostic and treatment of visual anomalies
US7767217B2 (en) 2006-03-14 2010-08-03 Foresight Biotherapeutics Ophthalmic compositions comprising povidone-iodine
US20120225918A1 (en) 2011-03-03 2012-09-06 Voom, Llc Compositions and Methods for Non-Surgical Treatment of Ptosis
KR102017916B1 (en) 2011-09-20 2019-09-03 알러간, 인코포레이티드 Compositions and methods for treating presbyopia, mild hyperopia, and irregular astigmatism
AU2014212274A1 (en) 2013-02-01 2015-08-13 Ocularis Pharma, Llc Aqueous ophthalmic solutions of phentolamine and medical uses thereof
DK2950800T3 (en) 2013-02-01 2020-11-16 Ocuphire Pharma Inc METHODS AND COMPOSITIONS FOR DAILY OPHTHALMIC ADMINISTRATION OF PHENTOLAMINE TO IMPROVE VISIBILITY
US20200121652A1 (en) * 2017-06-16 2020-04-23 The Doshisha Compounds having caspase inhibitory activity, pharmaceutical agent containing said compounds and for treating or preventing corneal endothelial symptoms, disorders, or diseases, and application of said pharmaceutical agent
US11433090B2 (en) 2017-06-16 2022-09-06 The Doshisha mTOR-inhibitor-containing medicine for treating or preventing ophthalmic symptoms, disorders, or diseases, and application thereof
US12161629B2 (en) 2018-10-15 2024-12-10 Opus Genetics, Inc. Methods and compositions for treatment of glaucoma and related conditions
SG11202104094YA (en) 2018-10-26 2021-05-28 Ocuphire Pharma Inc Methods and compositions for treatment of presbyopia, mydriasis, and other ocular disorders
CN115368310A (en) 2021-05-18 2022-11-22 奥库菲尔医药公司 Method for synthesizing phentolamine mesylate

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3658963A (en) 1970-07-07 1972-04-25 Warner Lambert Co Method of reducing intraocular pressure with a basic thymol ether
US3966779A (en) 1973-04-30 1976-06-29 Warner-Lambert Company Thymol derivatives and a process for their preparation
IT1094076B (en) 1978-04-18 1985-07-26 Acraf CICLOALCHILTRIAZOLI
IT1209160B (en) 1979-12-20 1989-07-10 Blasinachim Spa PROCESS FOR THE SYNTHESIS OF 4- [2- (DIMETHYLAMINE) -ETOXY] 2-METHYL-5-81-METHYLethyl) -PHENOL-ESTE RI
US4310524A (en) 1980-04-11 1982-01-12 Richardson-Merrell, Inc. TCA Composition and method for rapid onset antidepressant therapy
US5514672A (en) 1981-02-17 1996-05-07 Bazzano; Gail S. Use of retinoids and compositions containing same for hair growth
EP0062596B1 (en) 1981-04-06 1985-07-03 Cortial S.A. Derivatives of 4-aminoethoxy-5-isopropyl-2-methyl phenol, process for their preparation and their use as medicines
US4443441A (en) 1981-08-07 1984-04-17 Galin Miles A Fixation of intraocular lenses
US4490379A (en) 1984-04-04 1984-12-25 Steven Podos Method of reducing intraocular pressure and treating glaucoma using corynanthine
US4911920A (en) 1986-07-30 1990-03-27 Alcon Laboratories, Inc. Sustained release, comfort formulation for glaucoma therapy
US4795758A (en) 1986-02-10 1989-01-03 Societe A Responsabilite Limitee: Institut De Recherches Chimiques Et Biologiques Appliquees (I.R.C.E.B.A.) 5-[2-(pyrrolidin-1-yl)ethoxy]-p-cymene derivatives, the process for the preparation of the said derivatives and drugs in which the said derivatives are present
US4879304A (en) 1987-05-01 1989-11-07 Angelini Pharmaceuticals Ltd. Ophthalmic compositions and process for preparing
US4879294A (en) 1988-01-28 1989-11-07 Angelini Pharmaceuticals Ltd. Opthalmic composition
US5719197A (en) 1988-03-04 1998-02-17 Noven Pharmaceuticals, Inc. Compositions and methods for topical administration of pharmaceutically active agents
US5656286A (en) 1988-03-04 1997-08-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
US5446070A (en) 1991-02-27 1995-08-29 Nover Pharmaceuticals, Inc. Compositions and methods for topical administration of pharmaceutically active agents
CA1334168C (en) 1988-04-26 1995-01-31 Louis M. De Santis Antiglaucoma compositions containing combinations of .alpha.-2 agonists and .beta. blockers
IT1224250B (en) 1988-06-10 1990-09-26 Acraf ASSOCIATION OF DEPIPRAZOLE WITH MORFINA
US5116615A (en) 1989-01-27 1992-05-26 Immunolytics, Inc. Method for treating benign prostatic hypertrophy
US5182270A (en) 1989-08-03 1993-01-26 Iolab Corporation Stabilizing preparation for thymoxamine
US5660851A (en) 1989-12-26 1997-08-26 Yissum Research Development Company Of The Hebrew Univ. Of Jerusalem Ocular inserts
US5302172A (en) 1990-03-15 1994-04-12 North Carolina State University Method and composition for iontophoresis
IT1252603B (en) 1990-04-19 1995-06-19 Giorgio Cavallini 2,4-DIAMINO-6 PIPERIDINO PIRIMIDINA-3 TOPICAL OXIDE ON THE GLAND IN THE TREATMENT OF ERECTILE IMPOTENCES
IT1250701B (en) 1991-07-24 1995-04-21 Angelini Francesco Ist Ricerca SOLID PHARMACEUTICAL COMPOSITION FOR ORAL USE BASED ON DAPIPRAZOLE
US5459133A (en) 1992-06-05 1995-10-17 Telor Ophthalmic Pharmaceuticals, Inc. Methods and products for treating presbyopia
AU4653993A (en) 1992-07-02 1994-01-31 Telor Ophthalmic Pharmaceuticals, Inc. Methods and products for treating presbyopia
US5288759A (en) 1992-08-27 1994-02-22 Alcon Laboratories, Inc. Use of certain sulfamoyl-substituted phenethylamine derivatives to reverse drug-induced mydriasis
US5811547A (en) 1992-10-14 1998-09-22 Nippon Shinyaju Co., Ltd. Method for inducing crystalline state transition in medicinal substance
IT1264020B (en) 1993-01-28 1996-09-09 Recordati Chem Pharm PROCEDURE FOR THE PREPARATION OF MICROGRANULES SUITABLE FOR SUSPENSION IN LIQUIDS
US5321012A (en) 1993-01-28 1994-06-14 Virginia Commonwealth University Medical College Inhibiting the development of tolerance to and/or dependence on a narcotic addictive substance
FR2703908B1 (en) 1993-04-13 1995-06-02 Asta Medica Ag Pharmaceutical form for rectal administration of pharmacologically active compounds.
US5571177A (en) 1993-06-14 1996-11-05 Allergan IOL structured for post-operative re-positioning and method for post-operative IOL re-positioning
US5853751A (en) 1993-06-23 1998-12-29 Masiz; John J. Molecular transdermal transport system
US5565466A (en) 1993-08-13 1996-10-15 Zonagen, Inc. Methods for modulating the human sexual response
US5545626A (en) 1994-01-19 1996-08-13 The Trustees Of Columbia University In The City Of New York Method of treating glaucoma with oligonucleotides
JP2706755B2 (en) 1994-02-10 1998-01-28 日本たばこ産業株式会社 Novel benzylaminoethoxybenzene derivative
US5512577A (en) 1994-06-02 1996-04-30 Creighton University Bicyclic hexahydroaporphine and 1-benzyloctahydroisoquinoline therapeutic compositions and processes for utilizing said compositions
IL114193A (en) * 1994-06-20 2000-02-29 Teva Pharma Ophthalmic pharmaceutical compositions based on sodium alginate
US5451609A (en) 1994-07-27 1995-09-19 Institut De Recherches Chimiques Et Al Treatment of impotence
US5561154A (en) 1994-07-27 1996-10-01 Institut De Recherches Chimiques Et Bioloques Appliquees Irceba Treatment of acute urinary retention
FR2726770B1 (en) 1994-11-16 1997-01-31 Lhd Lab Hygiene Dietetique TRANSDERMAL DRUG DELIVERY DEVICE FOR THE TREATMENT OF MALE ERECTILE IMPOTENCE
US5972326A (en) 1995-04-18 1999-10-26 Galin; Miles A. Controlled release of pharmaceuticals in the anterior chamber of the eye
US5612027A (en) 1995-04-18 1997-03-18 Galin; Miles A. Controlled release of miotic and mydriatic drugs in the anterior chamber
US5731339A (en) 1995-04-28 1998-03-24 Zonagen, Inc. Methods and formulations for modulating the human sexual response
US5620416A (en) 1995-06-07 1997-04-15 North Carolina State University Methods of using topical agents with systemically administered active agents
US5795909A (en) 1996-05-22 1998-08-18 Neuromedica, Inc. DHA-pharmaceutical agent conjugates of taxanes
US6540990B2 (en) 2000-09-22 2003-04-01 Gerard M. Nolan Physiological method of improving vision
US6273092B1 (en) 2000-09-22 2001-08-14 Gerard M. Nolan Methods for treating various eye disorders

Also Published As

Publication number Publication date
EP1255540A1 (en) 2002-11-13
BR0108219A (en) 2004-04-27
CA2398158A1 (en) 2001-08-16
JP2003535817A (en) 2003-12-02
IL151171A0 (en) 2003-04-10
KR20030061301A (en) 2003-07-18
WO2001058438A1 (en) 2001-08-16
MXPA02007698A (en) 2004-09-10
US6730691B1 (en) 2004-05-04

Similar Documents

Publication Publication Date Title
AU2001236868A1 (en) Ophthalmic use of alpha adrenergic blocking agents
AU2001288577A1 (en) Laser polishing of medical devices
AU7862200A (en) Flip-wing tissue retainer
ATE229795T1 (en) SKIN-FRIENDLY HAND CLEANERS, ESPECIALLY BROAD HAND CLEANERS
AU3365401A (en) Use of ketotifen as ophthalmic agent
AU2001273052A1 (en) Antifungal compounds and methods of use
AU3328600A (en) Ocular tension-lowering agents
IL144662A0 (en) Use of cholesterol-lowering agent
AU2001252627A1 (en) Polybenzasol fiber and use of the same
GB2394900B (en) Ophthalmic devices and procedures
AU2457400A (en) Brush holder, use of the brush holder, brush and brush set
AUPR024300A0 (en) Tissue bonding agent
AU8737701A (en) Purification, characterization and use of protective antigenic structures against trypanosomes and related parasites
AU2001277750A1 (en) Use of polypeptide
AU2002221882A1 (en) Use of 3-hydroxyl-3-methylglutaryl-coenzyme-a-reductase inhibitors
EP1418907A4 (en) Novel alpha adrenergic agents
GB0015250D0 (en) Ophthalmic uses of lasers
AU2002356679A1 (en) Clusianon isomers and use thereof
AU2002316724A1 (en) Ophthalmic use of 5 fluorourcil
AU2001264002A1 (en) Acetazolamide-based ophthalmic solution
AU2002331036A1 (en) Novel alpha adrenergic agents
AU2002222093A1 (en) Goggles and masks
AU2002237189A1 (en) New use of phencynonate hydrochloride
AU2002238356A1 (en) New use of phencynonate hydrochloride
AU2002304858A1 (en) Ophthalmic compositions and use thereof